Synthorx is a biotechnology company using our proprietary synthetic biology platform starting with our novel DNA base pair, to discover and develop new protein therapeutics. We use new building blocks to create proteins that impart specificity not possible with native proteins. Our goal is to create treatments with improved efficacy, better safety, and better convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture novel proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics.
The company was founded by Avalon Ventures based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute in La Jolla, Calif. These discoveries include research published by the Romesberg lab in Nature, describing the first example of in vivo replication of a synthetic DNA base pair and the development of a semi-synthetic organism (read more here). Synthorx has the exclusive rights to this synthetic biology technology from The Scripps Research Institute. Investors include Avalon Ventures, Correlation Ventures, Medicxi, Orbimed, Osage University Partners, and RA Capital Management.